Tag Archives: Others

China Clears 11 Innovative Medical Devices for Special Review Track

Beijing, Aug 25, 2026 — China’s Center for Medical Device Evaluation (CMDE) unveiled the 14th batch of innovative medical device special review applications for 2026, clearing 11 products for an expedited regulatory pathway spanning advanced oncology therapy, cardiovascular implants, and brain-computer interfaces.

Regulatory Snapshot

Attribute	Detail
Issuer	Center for Medical Device Evaluation (CMDE), National Medical Products Administration
Document	Announcement of Review Results for Special Review Applications of Innovative Medical Devices (No. 14, 2026)
Legal basis	NMPA Announcement [2018] No. 83 (Special Review Procedure for Innovative Medical Devices)
Products cleared	11
Public comment period	Aug 25, 2026 – Sept 8, 2026
Contact	gcdivision@cmde.org.cn

Products Entering Special Review

The 11 devices span therapeutic areas from oncology to neurology:

No.	Product	Applicant	Category
1	Disposable Steep-Pulse Ablation Electrode Needle	Hunan Eweid Medical Device Co., Ltd.	Tumor ablation
2	Aortic Root Patch	Beijing Balance Medical Technology Co., Ltd.	Cardiovascular surgery
3	Aortic Valve Replacement System	Shenzhen Jianxin Medical Technology Co., Ltd.	Structural heart
4	Boron Neutron Capture Therapy System	Huapeng Boron Neutron Technology (Hangzhou) Co., Ltd.	Radiation oncology
5	Bioresorbable Left Atrial Appendage Occluder	Shanghai Shape Memory Alloy Material Co., Ltd.	Interventional cardiology
6	Artificial Corneal Endothelial Membrane Patch	Aiyan Medical Co., Ltd.	Ophthalmology
7	Implantable Brain-Computer Interface Neurostimulator	Beijing PINS Medical Equipment Co., Ltd.	Neurology / neurotechnology
8	Implantable Tibial Nerve Stimulation System	Hangzhou Shenluo Medical Technology Co., Ltd.	Neuromodulation
9	Human Circulating Tumor Molecular Residual Disease Detection Kit (CPA Sequencing)	Guangzhou Burning Rock Medical Laboratory Co., Ltd.	Oncology diagnostics
10	Focused Ultrasound Neuromodulation Device	Chongqing Haifu Medical Technology Co., Ltd.	Therapeutic ultrasound
11	Absorbable Dural Sealant Glue	Shandong Junxiu Biotechnology Co., Ltd.	Neurosurgery

Market Impact Analysis

The 14th batch highlights Beijing’s continued prioritization of high-risk, high-innovation devices that address unmet clinical needs. Notable entries include Huapeng Boron Neutron Technology’s boron neutron capture therapy (BNCT) system—a cutting-edge radiation modality for refractory cancers—and Beijing PINS Medical’s implantable brain-computer interface neurostimulator, reflecting China’s strategic push into neurotechnology and advanced neuromodulation.

Cardiovascular devices dominate the roster with three entries, including an aortic valve replacement system and a bioresorbable left atrial appendage occluder, signaling sustained investor and regulatory interest in structural heart interventions. The inclusion of an artificial corneal endothelial membrane patch and an absorbable dural sealant glue underscores expansion into specialized surgical niches with limited existing treatment options.

Burning Rock’s circulating tumor molecular residual disease (MRD) detection kit, using combined probe anchor polymerization sequencing, positions the company to compete in the rapidly growing minimal residual disease monitoring market, a segment increasingly valued for post-surgical cancer recurrence surveillance.

Regulatory Caveats

CMDE emphasized that the public announcement does not constitute formal admission into the special review procedure; final eligibility depends on conclusive review outcomes. Entry into the special review track does not equate to regulatory confirmation of safety or efficacy. Applicants must continue development and submit formal registration applications, which will be evaluated under early engagement, dedicated reviewer, and scientific review principles—without reduced standards or abbreviated procedures.

Forward-Looking Statement

Industry analysts expect the 11 devices to benefit from expedited CMDE review timelines, typically compressing standard approval cycles by 30% to 50% for innovative products. The batch’s diversity—from BNCT systems to brain-computer interfaces—suggests regulators are casting a wide net for breakthrough technologies rather than concentrating on a single therapeutic area. Companies with pipeline candidates in neuromodulation, advanced radiation therapy, and molecular diagnostics should view the special review pathway as increasingly accessible, though the caveat on unchanged evidentiary standards means clinical trial requirements remain rigorous. Final special review determinations are expected by late September 2026, barring substantive objections during the two-week comment window.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260825110558111.html

China Backs Centralized Production of Hospital Preparations in TCM

Leave a reply

Beijing, Aug 14, 2026 — China’s National Medical Products Administration (NMPA) endorsed centralized manufacturing models for hospital traditional Chinese medicine (TCM) preparations in an official reply to a National People’s Congress proposal, outlining a regulatory framework that shifts traditional formulas toward regional production hubs while tightening quality controls and streamlining filing requirements.

Policy Snapshot

Attribute	Detail
Document	Reply to Proposal No. 3936, 14th NPC 4th Session
Proposer	Deputy Fan Zhen
Issuers	NMPA; National Administration of Traditional Chinese Medicine
Key regulation	Revised Drug Administration Law Implementing Regulations (effective May 15, 2026)
Core focus	Hospital preparations; centralized production; regional formulation centers

Regulatory Streamlining

The NMPA highlighted that the revised Drug Administration Law Implementing Regulations, effective May 15, 2026, codify simplified pathways for hospital TCM preparations. Institutions using traditional preparation methods need only file with provincial regulators rather than seek full approval. Formulations with a five-year or longer clinical use history within the same hospital are exempt from pharmacodynamics and single- and repeat-dose toxicity studies.

The agency also clarified that outsourcing preparation no longer requires a separate regulatory license; hospitals need only file with provincial authorities as the delegating party. The rules mandate that hospital legal representatives and primary executives bear full responsibility for formulation quality, and require provincial regulators to decide on inter-hospital transfer applications within five working days.

The NMPA pointed to its 2023 measures on TCM scientific supervision, which encourage hospitals to use big data, artificial intelligence, and real-world evidence to study clinical positioning, target populations, and dosage regimens for institutional preparations. The framework explicitly supports converting proven hospital formulations with distinct advantages and low adverse-event profiles into new drug candidates.

Quality Safeguards

Regulators pledged intensified inspections of preparation and use processes, with particular scrutiny on outsourced manufacturing by small TCM clinics. The NMPA urged hospitals to establish pharmacovigilance systems for adverse reaction monitoring and endorsed multi-center clinical studies through inter-hospital transfers. The framework requires full traceability of raw materials, production controls, and quality testing.

Centralized Production Push

In the most significant policy signal, the NMPA and NATCM endorsed piloting regional formulation centers to enable shared production, unified quality control, and consolidated distribution of hospital TCM preparations. The agencies said they would draw on national drug traceability system experience to explore full-process digital tracking for institutional formulations, and will summarize local pilot experiences to refine centralized manufacturing and transfer policies.

Market Impact Analysis

The endorsement of regional formulation centers marks a structural shift for China’s hospital TCM sector, which has historically relied on fragmented in-house preparation labs. Centralized production could reduce per-unit manufacturing costs and standardize quality across institutions, but may force smaller hospitals to abandon independent formulation capabilities and rely on regional hubs.

The exemption of five-year traditional formulas from toxicity studies lowers the barrier for heritage formulations to achieve regulatory status, potentially accelerating the pipeline of hospital-developed drugs toward new drug conversion—a pathway the NMPA explicitly supports. For pharmaceutical contract manufacturers, the regional hub model creates new partnership opportunities with hospital networks, particularly in provinces with dense TCM institution clusters.

Forward-Looking Statement

Industry analysts expect the NMPA to release detailed regional formulation center guidelines within 12 to 18 months, following pilot program evaluations. The convergence of simplified filing rules, digital traceability mandates, and centralized production incentives suggests Beijing is positioning hospital TCM preparations as a controlled but strategically important bridge between traditional practice and modern pharmaceutical manufacturing. Companies with expertise in TCM formulation technology and pharmaceutical logistics are likely to benefit as provincial governments begin tendering regional hub contracts in late 2026 and 2027.-China Health Reform Pulse

Policy Source: https://www.nmpa.gov.cn/zwgk/jyta/rdjy/20260825155646136.html

Shanghai Renews Centralized Drug Procurement Contracts for Third Quarter

Leave a reply

Shanghai, Aug 24, 2026 — Shanghai’s Medical Procurement Center said it will renew centralized volume-based procurement contracts for selected drugs in the third quarter of 2026, extending agreements with winning manufacturers and their designated distributors after initial purchase volumes were fulfilled.

Policy Snapshot

Attribute	Detail
Issuer	Shanghai Medical Centralized Bidding and Procurement Affairs Management Center
Document	Notice on the Renewal of Selected Drugs in Centralized Procurement (Q3 2026)
Effective date	Sept 20, 2026
Scope	Selected drugs with expired procurement agreements and completed contracted volumes
Action	Renewal of tripartite purchase agreements among procurement center, winning manufacturers, and designated distributors

Key Provisions

Automatic renewal trigger — Contracts are extended for drugs that have reached the end of their initial procurement cycle and satisfied contracted purchase volumes under the volume-based procurement framework.
Tripartite structure — The procurement center will sign renewed purchase agreements directly with winning enterprises and their appointed distribution partners.
Complaint channel — Medical institutions are instructed to report any procurement issues to the procurement center during the renewal process.
Residual compliance — Unspecified matters will be governed by existing centralized procurement regulations and the terms of the tripartite agreements.

Market Impact Analysis

The renewal notice underscores Shanghai’s commitment to maintaining supply continuity under its volume-based procurement regime, a national pricing reform that has slashed drug costs by forcing manufacturers to bid aggressively for hospital market share. By automatically extending contracts for drugs that hit volume targets, regulators are signaling stability to winning suppliers while preventing supply disruptions that could arise from abrupt re-tendering.

For pharmaceutical companies, the renewal mechanism reduces regulatory uncertainty for products that have already secured centralized procurement slots, allowing them to plan production and distribution without navigating fresh bidding rounds. However, the notice also implicitly tightens compliance expectations—manufacturers must have fulfilled contracted volumes to qualify, penalizing those that struggled with supply or quality during the initial term.

Forward-Looking Statement

Industry observers expect the Q3 renewal wave to proceed without major disruption, given that eligible drugs have already demonstrated supply reliability. The Sept 20 effective date aligns with Shanghai’s typical procurement calendar, suggesting seamless transitions for hospital formularies. Looking ahead, the renewal template is likely to be replicated in other provincial procurement platforms as volume-based procurement contracts signed during the 2024-2025 national expansion cycle begin maturing, potentially triggering a broader wave of contract extensions across China’s public hospital network in 2027.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/08/24/24042.shtml